Feasibility of therapeutic drug monitoring of asparaginase across multiple formulations in pediatric acute lymphoblastic leukemia
Blood Research · 2026-12 · 61 (1)
DOI: 10.1007/s44313-026-00160-3 ↗Kurz gefasst
Leserbrief in der Zeitschrift Blood Research, online erschienen am 20.08.2026. Verfasst von Hyery Kim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea. taban@hanmail.n…. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea. taban@hanmail.net.
- Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea.
- Department of Pediatrics, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
Zitieren
APA
Kim, H., Yu, J., Yoon, S. H., Kang, S., Koh, K. N., & Im, H. J. (2026). Feasibility of therapeutic drug monitoring of asparaginase across multiple formulations in pediatric acute lymphoblastic leukemia. Blood Research, 61(1). https://doi.org/10.1007/s44313-026-00160-3
Vancouver
Kim H, Yu J, Yoon SH, Kang S, Koh KN, Im HJ. Feasibility of therapeutic drug monitoring of asparaginase across multiple formulations in pediatric acute lymphoblastic leukemia. Blood Research. 2026;61(1). doi:10.1007/s44313-026-00160-3
BibTeX
@article{Kim2026,
author = {Kim, Hyery and Yu, Juyeon and Yoon, Su Hyun and Kang, Sunghan and Koh, Kyung-Nam and Im, Ho Joon},
title = {Feasibility of therapeutic drug monitoring of asparaginase across multiple formulations in pediatric acute lymphoblastic leukemia},
journal = {Blood Research},
year = {2026},
volume = {61},
number = {1},
doi = {10.1007/s44313-026-00160-3}
}
EUVIMED